Shopping Cart 0
Cart Subtotal
USD 0

Inventiva (IVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Inventiva is a clinical stage biopharmaceutical company that discovers and develops therapies for fibrosis, oncology and orphan diseases. The company develops pipeline products for nonalcoholic steatohepatitis, systemic sclerosis, mucopolysaccharidosis, moderate to severe psoriasis, malignant mesothelioma, multiple myeloma, immuno-oncology and idiopathic pulmonary fibrosis indications. It develops a novel internal cancer and fibrosis discovery pipeline with nuclear receptor platform, epigenetic platform, fibriva, DMPK, ivalib and screening platforms, pharmacology, and target validation. The company advances small-molecule therapies for auto-immune disorders and operates the Epicure project. It conducts its drug discovery research in partnership with various medical organizations. Inventiva is headquartered in Daix, France.

Inventiva (IVA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Inventiva, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Inventiva, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Inventiva, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Inventiva, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Inventiva, Medical Devices Deals, 2012 to YTD 2018 10

Inventiva, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Inventiva, Pharmaceuticals & Healthcare, Deal Details 12

Private Equity 12

Inventiva Pharma Raises USD43.8 Million in Private Placement of Shares 12

Partnerships 14

Curie-Cancer Partners with Inventiva 14

NovAliX Enters Into Agreement With Inventiva For Nuclear Receptor Drug Discovery 15

Inventiva Extends Agreement with AbbVie 16

Licensing Agreements 17

Boehringer Ingelheim Exercises Option for Licensing Agreement with Inventiva 17

Equity Offering 18

Inventiva Plans to Raise USD37 Million in Private Placement of Shares 18

Inventiva Raises USD53 Million in IPO 20

Inventiva-Key Competitors 21

Inventiva-Key Employees 22

Inventiva-Locations And Subsidiaries 23

Head Office 23

Recent Developments 24

Financial Announcements 24

Jul 19, 2018: Inventiva reports first-half 2018 financial results and provides corporate update 24

May 15, 2018: Inventiva: First-quarter 2018 financial update 26

Mar 07, 2018: Inventiva: 2017 Full Year Results 28

Feb 12, 2018: Inventiva Reports Full-Year 2017 Financial Results 30

Nov 07, 2017: Inventiva: Third-Quarter 2017 Financial Information 32

Sep 26, 2017: Inventiva: First-Half 2017 Results 33

Jul 05, 2017: Inventiva Announces First-half 2017 Financial and Corporate Update 37

Apr 25, 2017: Inventiva: First-Quarter 2017 Financial Update 39

Corporate Communications 40

Oct 17, 2018: Inventiva announces two appointments to its management team ahead of future key development milestones 40

May 28, 2018: Dr Lucy Lu is appointed to the Inventiva Board of Directors 41

May 30, 2017: Dr Nanna Luneborg, Principal of Novo Ventures, Joins Inventiva's Board 42

Product News 43

07/27/2017: Inventiva to Present New Data on IVA337 at the 15th International Workshop on Scleroderma Research in Pittsburgh, USA 43

Clinical Trials 44

Sep 18, 2017: Inventivas IVA337 Given Generic Name Lanifibranorby the World Health Organization (WHO) 44

Jun 20, 2017: Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models 45

May 15, 2017: Inventiva Announces Positive Results of 12 Month Primate Toxicity Study with IVA337 46

Apr 20, 2017: Inventiva Announces Presentation of Preclinical Results on IVA337 in NASH at the International Liver Congress 2017 47

Apr 10, 2017: Inventiva Hits Clinical Milestone with Enrollment of 100th Patient in IVA337 Phase 2b FASST Trial in Systemic Sclerosis 48

Jan 03, 2017: Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis 49

Other Significant Developments 50

Sep 24, 2018: Inventiva launches an independent working group to help increase NASH awareness and establish best practices for its treatment 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

Inventiva, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Inventiva, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Inventiva, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Inventiva, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Inventiva, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Inventiva, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Inventiva, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Inventiva, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Inventiva, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Inventiva, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Inventiva, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Inventiva, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Inventiva, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Inventiva, Deals By Therapy Area, 2012 to YTD 2018 9

Inventiva, Medical Devices Deals, 2012 to YTD 2018 10

Inventiva, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Inventiva Pharma Raises USD43.8 Million in Private Placement of Shares 12

Curie-Cancer Partners with Inventiva 14

NovAliX Enters Into Agreement With Inventiva For Nuclear Receptor Drug Discovery 15

Inventiva Extends Agreement with AbbVie 16

Boehringer Ingelheim Exercises Option for Licensing Agreement with Inventiva 17

Inventiva Plans to Raise USD37 Million in Private Placement of Shares 18

Inventiva Raises USD53 Million in IPO 20

Inventiva, Key Competitors 21

Inventiva, Key Employees 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Inventiva, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.